JET-INJECTED INSULIN IS ASSOCIATED WITH DECREASED ANTIBODY-PRODUCTION AND POSTPRANDIAL GLUCOSE VARIABILITY WHEN COMPARED WITH NEEDLE-INJECTED INSULIN IN GESTATIONAL DIABETIC WOMEN

OBJECTIVE- To elucidate the glycemic response and antibody formation in gestational diabetic women treated with insulin injected by a needle or a jet. The American Diabetes Association's position statement on jet injectors raised the concern that ''insulin could be denatured as a result of forceful injection through a tiny port, which could lead to an increase in antibody formation'' (Diabetes Care 11:600, 1988). However, the pharmacokinetics of jet-injected insulin suggest that it might be useful in controlling postprandial glucose levels. METHODS- We randomized 20 women with gestational diabetes mellitus (<34 wk gestation) who required insulin to receive either jet-injected or needle-injected human NPH and regular insulin. Variables of interest were evaluated at the start of therapy, weekly until delivery, and 6-wk postpartum that included: 1) insulin antibodies in the mother and her infant, 2) HbA1c, 3) insulin dose, 4) fasting and postprandial glucose levels, and 5) subject acceptance and preference. RESULTS- Of the 10 women in the needle group, 6 developed significant insulin antibodies compared with 1 of 10 in the jet group (P < 0.001). HbA1c and insulin doses were the same in both groups. During the test meal, glucose levels in the jet group were significantly lower (P < 0.01), yet none of the women in the jet group experienced blood glucose <70 mg/dl (3.89 mM) at 3-4 h after the meal, compared with 5 in the needle group (P < 0.001). Jet injection was associated with less variability (P < 0,001) in postprandial glucose values but slightly greater variability (P < 0.05) in fasting glucose. jet-injected insulin was more readily accepted by subjects than needle injections. CONCLUSIONS- Jet injection is associated with a diminished antibody response and postprandial variability compared with needle-injected insulin. Thus, this warrants consideration as a therapeutic option for women with gestational diabetes mellitus and may also be applicable to nonpregnant, insulin-requiring diabetic patients.